Marker Therapeutics, Inc.

Tagged: board of directors

Marker Therapeutics Appoints Steve Elms to its Board of Directors

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced the appointment of Steve Elms, to its Board of Directors, effective August 6.

Read More

TapImmune Announces Change in Management and Board of Directors

TapImmune Inc. announced that on April 28,2017, Dr. John Bonfiglio resigned as Chief Operating Officer, President and director of TapImmune Inc. to pursue other opportunities.

Read More

TapImmune Appoints Frederick G. Wasserman to its Board of Directors

…TapImmune Inc. (OTCMKTS: TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, is pleased to announce the appointment of Frederick G. Wasserman to its Board as an Independent Director.

Frederick (Rick) is an accomplished Board Director with 35 years of business experience.

Read More

TapImmune Appoints David Laskow-Pooley, CEO of London Pharma, to its Board of Directors

…SEATTLE, March 19, 2015 – TapImmune Inc. (OTCBB: TPIV) is pleased to announce the appointment of David Laskow-Pooley to the Company’s Board of Directors.

David brings 30 years of experience in all aspects of the discovery, development and commercialization of pharmaceutical and healthcare products. He has a successful track record of building, developing, operating and exiting start-up businesses, spin-outs from large corporations and business entities within large companies.

Read More